For decades, cisplatin-based chemotherapy before radical bladder removal has been the best available option for muscle-invasive bladder cancer — a disease with stubbornly poor long-term outcomes. A Phase 3 randomized trial now challenges that standard directly, testing whether an antibody-drug conjugate paired with immunotherapy can outperform the established regimen even in patients who are fit enough to tolerate cisplatin.
The EV-302/KEYNOTE-A39 perioperative trial enrolled 808 adults with muscle-invasive bladder cancer across both treatment arms: 405 received neoadjuvant enfortumab vedotin (1.25 mg/kg on days 1 and 8) plus pembrolizumab (200 mg on day 1) every three weeks for four cycles, followed by radical cystectomy, then up to five additional cycles of enfortumab vedotin and 13 cycles of pembrolizumab as adjuvant therapy. The comparator arm of 403 participants received standard neoadjuvant cisplatin-gemcitabine for four cycles before surgery, with no adjuvant systemic therapy. With a median follow-up of approximately 33.6 months, the primary endpoint of event-free survival and key secondary endpoints of overall survival and pathological complete response were assessed. The excerpt indicates 86.7% of the enfortumab vedotin-pembrolizumab arm completed neoadjuvant treatment, suggesting meaningful tolerability in a cisplatin-eligible population.
The significance here extends well beyond bladder cancer. Enfortumab vedotin, which targets Nectin-4 overexpressed on urothelial cells, previously transformed the metastatic setting alongside pembrolizumab in the EV-302 trial. Extending that combination into the curative-intent perioperative window — and measuring it against cisplatin in patients who could tolerate either — represents a genuine inflection point in urothelial oncology. If event-free and overall survival advantages are confirmed in the full data, this could redefine neoadjuvant treatment selection regardless of cisplatin eligibility status. Key caveats remain: this is a single Phase 3 trial requiring independent replication, the open-label design introduces potential bias in outcome assessment, and longer follow-up will be needed to determine whether pathological complete response translates into durable cure-rate improvement. Nonetheless, the design rigor and population size position this as a potentially paradigm-shifting dataset for bladder cancer management.